Evidence map›Paper›PMID 29981054›Full record

ArticleMolecular neurobiology2019

Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.

Katiuscia Pagano, Denise Galante, Cristina D'Arrigo, Alessandro Corsaro, Mario Nizzari, Tullio Florio, Henriette Molinari, Simona Tomaselli, Laura Ragona

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. The multiple functions of PrPJournal of molecular medicine (Berlin, Germany) · 2022
    Review
  4. Article
  5. The Toxicity and Polymorphism of β-Amyloid Oligomers.International journal of molecular sciences · 2020
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Katiuscia PaganoIstituto per lo Studio delle Macromolecole (ISMAC), CNR, Milan, Italy.
Denise GalanteISMAC, CNR, Genoa, Italy.
Cristina D'ArrigoISMAC, CNR, Genoa, Italy.
Alessandro CorsaroSection of Pharmacology, Department of Internal Medicine, and Center of Excellence for Biomedical research (CEBR), University of Genoa, Genoa, Italy.
Mario NizzariSection of Pharmacology, Department of Internal Medicine, and Center of Excellence for Biomedical research (CEBR), University of Genoa, Genoa, Italy.
Tullio FlorioSection of Pharmacology, Department of Internal Medicine, and Center of Excellence for Biomedical research (CEBR), University of Genoa, Genoa, Italy.
Henriette MolinariIstituto per lo Studio delle Macromolecole (ISMAC), CNR, Milan, Italy.
Simona TomaselliIstituto per lo Studio delle Macromolecole (ISMAC), CNR, Milan, Italy. simona.tomaselli@ismac.cnr.it.
Laura RagonaIstituto per lo Studio delle Macromolecole (ISMAC), CNR, Milan, Italy. laura.ragona@ismac.cnr.it.ORCID http://orcid.org/0000-0003-3893-7117
Institute for Macromolecular Studies · ITUniversity of Genoa · IT

Funding

Alzheimer's Association NIRG-14-321500Fondazione Cariplo 2015-0503
6 · The paper itself

Abstract

Soluble Aβ oligomers are widely recognized as the toxic forms responsible for triggering AD, and Aβ receptors are hypothesized to represent the first step in a neuronal cascade leading to dementia. Cellular prion protein (PrP) has been reported as a high-affinity binder of Aβ oligomers. The interactions of PrP with both Aβ42 and the highly toxic N-truncated pyroglutamylated species (AβpE3-42) are here investigated, at a molecular level, by means of ThT fluorescence, NMR and TEM. We demonstrate that soluble PrP binds both Aβ42 and AβpE3-42, preferentially interacting with oligomeric species and delaying fibril formation. Residue level analysis of Aβ42 oligomerization process reveals, for the first time, that PrP is able to differently interact with the forming oligomers, depending on the aggregation state of the starting Aβ42 sample. A distinct behavior is observed for Aβ42 1-30 region and C-terminal residues, suggesting that PrP protects Aβ42 N-tail from entangling on the mature NMR-invisible fibril, consistent with the hypothesis that Aβ42 N-tail is the locus of interaction with PrP. PrP/AβpE3-42 interactions are here reported for the first time. All interaction data are validated and complemented by cellular tests performed on Wt and PrP-silenced neuronal cell lines, clearly showing PrP dependent Aβ oligomer cell internalization and toxicity. The ability of soluble PrP to compete with membrane-anchored PrP for binding to Aβ oligomers bears relevance for studies of druggable pathways.

Indexed as

Amyloid beta-PeptidesAnimalsBinding SitesCell LineCell SurvivalMagnetic Resonance SpectroscopyMiceNeuronsPeptide FragmentsPrion ProteinsProtein BindingAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsPrion ProteinsAlzheimer diseaseAmyloid beta peptidesCell internalizationCellular prion proteinInteraction studiesNuclear magnetic resonance

Identifiers

PMID29981054
OpenAlexW2816731458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.